Cargando…
Durvalumab: A Review in Extensive-Stage SCLC
Durvalumab (IMFINZI(®)), a fully human monoclonal antibody against programmed cell death-ligand 1 (PD-L1), is approved for use in combination with etoposide and either carboplatin or cisplatin for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC). In the pivo...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648650/ https://www.ncbi.nlm.nih.gov/pubmed/34731446 http://dx.doi.org/10.1007/s11523-021-00843-0 |